Mary Moynihan

CAMBRIDGE, Mass., April 30, 2025— Mission BioCapital (MBC) announced today that it has expanded the reach of its Platinum Program in Europe in a collaboration with BioInnovation Institute (BII), a Denmark-based nonprofit institute focused on accelerating life sciences innovation to benefit human and planetary health. Winners of this year’s Platinum Program are eligible for lab […]

— Up to 8 winners to receive up to $500,000 each in pre-seed funding, incubator space, equity for discovery services, and expert mentorship— CAMBRIDGE, Mass., April 7, 2025— Mission BioCapital (MBC), in partnership with sponsors Eli Lilly and Company (Lilly), Ono Venture Investment (OVI), Alloy Therapeutics, and our newest sponsor, HitGen, announced today that applications

— Pilot & first-year Platinum Program has provided eight companies pre-seed funding totaling $3.5 million, lab space, and mentorship and is now offering drug discovery and corporate advisory services from new sponsors Alloy Therapeutics, Goodwin, and van den Boom & Associates — CAMBRIDGE, Mass., October 30, 2024— Mission BioCapital (MBC) announced today the first eight

— Up to 6 winners are eligible for up to $3 million in seed funding, incubator space, $1 million in total equity for discovery services from Alloy Therapeutics, and expert mentorship — CAMBRIDGE, Mass., May 1, 2024— Mission BioCapital (MBC), in partnership with founding sponsors Eli Lilly and Company (Lilly) and Ono Venture Investment (OVI)

— Following success of 2022 pilot, MBC boosts 2023 program with substantially increased funding, geographic reach, and scientific expertise — — Applications now open — CAMBRIDGE, Mass., June 12, 2023—— Mission BioCapital (MBC) announced today the launch of the Mission BioCapital Platinum Program 2023 to identify and support high-potential life sciences startup companies. In collaboration

Underrepresented biotech founders developing novel health solutions will gain access to LabCentral’s lab space, resources and community CAMBRIDGE, Mass., Oct. 5, 2022— LabCentral Ignite, with support from key sponsors Pfizer, Bristol Myers Squibb and Mission BioCapital, today announced the winners of its second annual Golden Ticket contest: Cellens, Guardian Bio, QurCan Therapeutics and Spheric Bio.

Offers opportunity for underrepresented biotech entrepreneurs to benefit from LabCentral’s lab space, shared resources and community CAMBRIDGE, Mass., June 21, 2022— LabCentral, with support from Pfizer, Bristol Myers Squibb (BMS) and Mission BioCapital, today announced the launch of its second annual LabCentral Ignite Golden Ticket contest, designed to support diverse, underrepresented biotech entrepreneurs who are

Mission BioCapital to support female entrepreneurs with a $100K Mission BioCapital Award in the 2022 MassNextGen program round March 28, 2022— Today, the Massachusetts Life Sciences Center (MLSC) announced Mission BioCapital as the newest sponsor for the MLSC’s Massachusetts Next Generation Initiative (MassNextGen), a competitive program for women-led life sciences companies. Mission BioCapital is sponsoring

Record new fund to help biopharma startups achieve pivotal early-stage growth CAMBRIDGE, Mass. & SAN FRANCISCO, November 4, 2021— Mission BioCapital, a venture capital firm focused on making investments in early-stage life sciences companies that it uniquely supports as they grow, announced it has raised $275 million for its next round of investments. Mission BioCapital